Full-Time

Account Executive

Screening Sales

Posted on 5/16/2025

Guardant Health

Guardant Health

1,001-5,000 employees

Blood-based tests for cancer detection and management

No salary listed

Mid, Senior

Austin, TX, USA

Field-based role requiring daily travel within assigned territory.

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Salesforce
Customer Service
Requirements
  • 4+ years of direct experience in a customer-facing sales role in the healthcare industry (diagnostics, medical device and/or pharmaceutical sales) with a solid history of consistent closing abilities and proven past performance that has met and exceeded expectations
  • Comfortable communicating, presenting, selling to healthcare providers and office staff members
  • Impeccable oral and verbal communication and presentation skills; superior listening and problem-solving skills
  • Ability to engage in a consultative selling process that overcomes objections and indifferences while connecting client needs with GH capabilities
  • Ability to maintain an outstanding level of market, customer, distribution and product knowledge necessary to accomplish sales objectives
  • Excellent negotiation, problem-solving and customer service skills
  • Ability to handle sensitive information and maintain a very high level of confidentiality
  • Demonstrate ability to develop and utilize cross-functional relationships to facilitate the accomplishment of work goals and objectives
  • Ability to work independently, communicate proactively, manage multiple projects and prioritize daily tasks while managing critical deadlines
  • Ability to work effectively with minimal direction
  • Strong administrative skills to manage business in complex environments
  • Must be proficient at in person, phone and virtual selling environments
  • Must be very proficient with all Microsoft Office products & CRM systems (preferably Salesforce and Veeva)
  • Demonstrate Guardant Health values by acting with integrity, respect, trust and possess a very positive attitude and an understanding of the dynamics involved with organizational growth and change.
Responsibilities
  • Prospect and target healthcare providers for high utilization of SHIELD to screen patients for CRC and other cancers
  • Meet or exceed sales goals, maximize promotional budgets, and execute the national sales strategy in accordance with Guardant Health standards
  • Drive strategic business expansion/collaboration opportunities with primary care providers and their practices
  • Develop and implement a business plan in line with brand strategy to support launch
  • Identify and partner with national, regional and local laboratories that offer phlebotomy draw agreements
  • Initiate and secure lab service draw agreements, in-service and train specimen collection, workflow
  • Identify opportunities in the marketplace, share best practices, and proactively communicate strategies to cross-functional partners and members of the Commercial Team
  • Continually analyze competitive landscape and environment within assigned accounts to determine trends and provide customer feedback to GHI leadership
  • Structure detailed strategic plans for gaining and retaining new and existing clients
  • Manage implementation of all promotional activities to support sales and marketing strategies, in accordance with high industry standards and company policies
  • Work effectively with individuals across multiple departments throughout Guardant Health
  • Collaborate and coordinate with sales team to ensure successful attainment of company goals and objectives
  • Embrace, embody and represent the Guardant Health company culture at all times to external and internal constituents
  • This is a field-based role – must have ability to travel daily within assigned territory and some travel outside of assigned area for regional or national meetings
  • Uphold company mission and values through accountability, innovation, integrity, quality, and teamwork
  • Support and comply with the company’s Quality Management System policies and procedures.
Desired Qualifications
  • Experience with sales/marketing of diagnostic products (blood-based testing and/or phlebotomy) directly to primary care healthcare providers and their practices
  • Product launch planning and launch execution experience
  • Familiarity with primary care practice landscape in territory
  • High-touch customer service skills

Guardant Health specializes in blood-based tests that provide essential information for cancer treatment and management. Their main product, Guardant360, is an FDA-approved test that helps healthcare providers make informed treatment decisions for patients with advanced cancer. The tests work by analyzing blood samples to detect cancer and monitor its progression, allowing for non-invasive diagnostics. Unlike many competitors, Guardant Health focuses on providing data-rich insights that can be used at various stages of cancer, including early detection and recurrence monitoring. The company's goal is to enhance patient outcomes and lessen the impact of cancer through innovative diagnostic solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Guardant Health won the 2025 World Changing Ideas Award for colorectal cancer screening.
  • They partnered with Pfizer to develop cancer therapies using liquid biopsy technology.
  • Guardant Health is expanding into early-stage cancer detection and recurrence monitoring.

What critics are saying

  • Increased competition from Caris Life Sciences may impact market share and pricing power.
  • Rapid technological advancements may outpace Guardant Health's product integration capabilities.
  • Expansion into hereditary cancer testing may lead to increased regulatory scrutiny.

What makes Guardant Health unique

  • Guardant Health specializes in blood-based tests for cancer treatment and management.
  • Their flagship product, Guardant360, is FDA-approved for advanced cancer treatment decisions.
  • They focus on non-invasive diagnostics to improve patient outcomes and reduce cancer burden.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↑ 0%

2 year growth

↓ -1%
Guardant Health
Jun 10th, 2025
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Guardant Health wins Fast Company's 2025 World Changing Ideas Award for Shield blood test for colorectal cancer screening.

NNB5
Jun 9th, 2025
Caris Life Sciences, backed by Sixth Street, targets a $5.35 billion valuation in its upcoming U.S. IPO

Competitive landscape: Caris competes with Roche's Foundation Medicine, Guardant Health, Grail, and peers like Tempus AI.

PR Newswire
Jun 4th, 2025
Leading Health Groups Launch Effort To Encourage Modernization Of Health Screening Measures

WASHINGTON, June 4, 2025 /PRNewswire/ -- A collection of public and private sector health leaders today announced a new collaboration to help ensure current health screening measures remain aligned with the rapid advancements in FDA-approved screening technologies and clinical guidelines.The Alliance for Screening Measurement Modernization (ASMM) brings together organizations from across the healthcare sector to explore a broader framework for the timely integration of evidence into currently endorsed national health screening policies."It is critically important that clinicians have what they need to keep patients healthy, including the latest diagnostics," said Lee Fleisher, M.D., M.L., ASMM chair and founder of Rubrum Advising. "The pace of technology is accelerating rapidly, but it can take more than a decade to update the quality measures that assess compliance with current health screening recommendations. This means clinicians are not incentivized to use tests that may be quicker, safer, or less invasive for patients simply because they are built on technologies that have not yet been incorporated into the latest quality measures."Over the next six months, ASMM will:Develop a replicable, transparent framework to support measure developers with timely and appropriate pathways to update currently endorsed screening quality measuresto support measure developers with timely and appropriate pathways to update currently endorsed screening quality measures Enable the evidence-based inclusion of innovative technologies that improve diagnostic speed, accuracy, and accessibilitythat improve diagnostic speed, accuracy, and accessibility Submit a consensus white paper and policy briefs to Congressional and federal agencies for considerationASMM is led by two independent but collaborative bodies: the ASMM Quality Council, whose members are guideline-setting groups and non-profit organizations, and the Industry Council, which includes organizations that are at the forefront of transforming screening technologies to support more accurate, accessible, and timely diagnoses.The Quality Council is developing the framework and will operate independently of the Industry Council, which serves as the central forum to ensure diagnostic and imaging innovators and stakeholders have a voice in the process. Together, the councils represent a range of therapeutic areas and reflect expertise in both clinical practice and quality measure development and policy.Industry Council founding members include Geneoscopy and Guardant Health and founding members of the Quality Council include ECRI, Friends of Cancer Research, Milken Institute's FasterCures, URAC, and others.SOURCE The Alliance for Screening Measurement Modernization

Insider Monkey
May 31st, 2025
Guardant Health, Inc. (GH)'s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients

Guardant Health, Inc. (NASDAQ:GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at the 2025 ASCO Annual Meeting.

Guardant Health
May 27th, 2025
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

Guardant Health introduces nearly a dozen groundbreaking Smart Liquid Biopsy applications for Guardant360 Liquid test.

INACTIVE